Literature DB >> 8623535

Domains of the E1 protein of human papillomavirus type 33 involved in binding to the E2 protein.

F Müller1, M Sapp.   

Abstract

Papillomavirus E1 and E2 proteins are essential for the initiation of viral DNA replication. We have now analyzed the interaction of E1 and E2 of human papillomavirus type 33, which is associated with cervical carcinoma. When synthesized in insect cells using the baculovirus expression system, the E1 and E2 proteins interacted efficiently at 4 degree. A monoclonal antibody recognizing E1 amino acids 584--600 inhibited the binding of E2 and vice versa, indicating that these amino acids are involved in E2 binding. To confirm this result, a mutational analysis of E1 was performed. The E2 binding activity of E1 deletion and point mutant proteins was assayed using glutathione S-transferase E1 fusion proteins and in vitro translated proteins. At 4 degree, the C-terminal portion of E1 including amino acids 312--644 was sufficient for E2 binding. Introduction of C-terminal deletions or a point mutation at position 586 (Pro --> Glu) resulted in the loss of the E2 binding activity. A second more N-terminally located binding domain (E1 amino acids 312--450) became active when the assays were performed at 22 degrees. The monoclonal antibody still inhibited E2 binding at this temperature, indicating that both E2 binding domains are engaged in the context of the full-length protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623535     DOI: 10.1006/viro.1996.0242

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  13 in total

Review 1.  The E1 proteins.

Authors:  Monika Bergvall; Thomas Melendy; Jacques Archambault
Journal:  Virology       Date:  2013-09-10       Impact factor: 3.616

2.  Transient viral DNA replication and repression of viral transcription are supported by the C-terminal domain of the bovine papillomavirus type 1 E1 protein.

Authors:  M C Ferran; A A McBride
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

3.  Isolation of an amino-terminal region of bovine papillomavirus type 1 E1 protein that retains origin binding and E2 interaction capacity.

Authors:  X Leng; J H Ludes-Meyers; V G Wilson
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

4.  Generation and neutralization of pseudovirions of human papillomavirus type 33.

Authors:  F Unckell; R E Streeck; M Sapp
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  A conserved regulatory module at the C terminus of the papillomavirus E1 helicase domain controls E1 helicase assembly.

Authors:  Stephen Schuck; Arne Stenlund
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

6.  Role of the ATP-binding domain of the human papillomavirus type 11 E1 helicase in E2-dependent binding to the origin.

Authors:  S Titolo; A Pelletier; F Sauvé; K Brault; E Wardrop; P W White; A Amin; M G Cordingley; J Archambault
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  A conserved amphipathic helix in the N-terminal regulatory region of the papillomavirus E1 helicase is required for efficient viral DNA replication.

Authors:  Geneviève Morin; Amélie Fradet-Turcotte; Paola Di Lello; Fanny Bergeron-Labrecque; James G Omichinski; Jacques Archambault
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

8.  Human papillomavirus DNA replication compartments in a transient DNA replication system.

Authors:  C S Swindle; N Zou; B A Van Tine; G M Shaw; J A Engler; L T Chow
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  A C-terminal helicase domain of the human papillomavirus E1 protein binds E2 and the DNA polymerase alpha-primase p68 subunit.

Authors:  P J Masterson; M A Stanley; A P Lewis; M A Romanos
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 10.  Papillomavirus E1 proteins: form, function, and features.

Authors:  Van G Wilson; Michael West; Kelly Woytek; Dandapani Rangasamy
Journal:  Virus Genes       Date:  2002-06       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.